359 related articles for article (PubMed ID: 15824180)
21. Geographic excess of estrogen receptor-positive breast cancer.
Benz CC; Clarke CA; Moore DH
Cancer Epidemiol Biomarkers Prev; 2003 Dec; 12(12):1523-7. PubMed ID: 14693747
[TBL] [Abstract][Full Text] [Related]
22. Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy.
Adepoju LJ; Symmans WF; Babiera GV; Singletary SE; Arun B; Sneige N; Pusztai L; Buchholz TA; Sahin A; Hunt KK; Meric-Bernstam F; Ross MI; Ames FC; Kuerer HM
Cancer; 2006 Jan; 106(1):42-50. PubMed ID: 16333852
[TBL] [Abstract][Full Text] [Related]
23. Risk of mortality by histologic type of breast cancer among women aged 50 to 79 years.
Li CI; Moe RE; Daling JR
Arch Intern Med; 2003 Oct; 163(18):2149-53. PubMed ID: 14557212
[TBL] [Abstract][Full Text] [Related]
24. Ductal carcinoma in situ: trends in geographic, temporal, and demographic patterns of care and survival.
Joslyn SA
Breast J; 2006; 12(1):20-7. PubMed ID: 16409583
[TBL] [Abstract][Full Text] [Related]
25. Ductal carcinoma in situ: trends in treatment over time in the US.
Zujewski JA; Harlan LC; Morrell DM; Stevens JL
Breast Cancer Res Treat; 2011 May; 127(1):251-7. PubMed ID: 20931276
[TBL] [Abstract][Full Text] [Related]
26. [Trends in incidence and treatment of ductal carcinoma in situ of the breast in southeast Netherlands].
Voogd AC; Crommelin MA; Repelaer van Driel OJ; Nolthenius-Puylaert MC; van der Heijden LH; Coebergh JW
Ned Tijdschr Geneeskd; 2000 Apr; 144(14):659-63. PubMed ID: 10774294
[TBL] [Abstract][Full Text] [Related]
27. Age-related lobular involution and risk of breast cancer.
Milanese TR; Hartmann LC; Sellers TA; Frost MH; Vierkant RA; Maloney SD; Pankratz VS; Degnim AC; Vachon CM; Reynolds CA; Thompson RA; Melton LJ; Goode EL; Visscher DW
J Natl Cancer Inst; 2006 Nov; 98(22):1600-7. PubMed ID: 17105983
[TBL] [Abstract][Full Text] [Related]
28. Lobular carcinoma of the breast in situ and infiltrating.
Wheeler JE; Enterline HT
Pathol Annu; 1976; 11():161-88. PubMed ID: 188001
[TBL] [Abstract][Full Text] [Related]
29. Carcinoma in situ of the female breast. 10 year follow-up results of a prospective nationwide study.
Ottesen GL; Graversen HP; Blichert-Toft M; Christensen IJ; Andersen JA
Breast Cancer Res Treat; 2000 Aug; 62(3):197-210. PubMed ID: 11072784
[TBL] [Abstract][Full Text] [Related]
30. Lobular neoplasia. Long term risk of breast cancer and relation to other factors.
Bodian CA; Perzin KH; Lattes R
Cancer; 1996 Sep; 78(5):1024-34. PubMed ID: 8780540
[TBL] [Abstract][Full Text] [Related]
31. Breast cancer in Tunisia in 2004: a comparative clinical and epidemiological study.
Maalej M; Hentati D; Messai T; Kochbati L; El May A; Mrad K; Romdhane KB; Ben Abdallah M; Zouari B
Bull Cancer; 2008 Feb; 95(2):E5-9. PubMed ID: 18304901
[TBL] [Abstract][Full Text] [Related]
32. Paget disease of the breast: changing patterns of incidence, clinical presentation, and treatment in the U.S.
Chen CY; Sun LM; Anderson BO
Cancer; 2006 Oct; 107(7):1448-58. PubMed ID: 16933329
[TBL] [Abstract][Full Text] [Related]
33. Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ.
Tuttle TM; Jarosek S; Habermann EB; Arrington A; Abraham A; Morris TJ; Virnig BA
J Clin Oncol; 2009 Mar; 27(9):1362-7. PubMed ID: 19224844
[TBL] [Abstract][Full Text] [Related]
34. Trends in incidence rates of invasive lobular and ductal breast carcinoma.
Li CI; Anderson BO; Daling JR; Moe RE
JAMA; 2003 Mar; 289(11):1421-4. PubMed ID: 12636465
[TBL] [Abstract][Full Text] [Related]
35. The management of ductal carcinoma in situ of the breast: a screened population-based analysis.
Rakovitch E; Pignol JP; Chartier C; Hanna W; Kahn H; Wong J; Mai V; Paszat L
Breast Cancer Res Treat; 2007 Mar; 101(3):335-47. PubMed ID: 16838110
[TBL] [Abstract][Full Text] [Related]
36. Screening caused rising incidence rates of ductal carcinoma in situ of the breast.
van Steenbergen LN; Voogd AC; Roukema JA; Louwman WJ; Duijm LE; Coebergh JW; van de Poll-Franse LV
Breast Cancer Res Treat; 2009 May; 115(1):181-3. PubMed ID: 18516674
[TBL] [Abstract][Full Text] [Related]
37. [Lobular carcinoma in situ (LCIS): risk factor and precursor of invasive lobular breast cancer].
Aulmann S; Penzel R; Schirmacher P; Sinn HP
Verh Dtsch Ges Pathol; 2007; 91():208-13. PubMed ID: 18314616
[TBL] [Abstract][Full Text] [Related]
38. Clinicopathologic implications of E-cadherin reactivity in patients with lobular carcinoma in situ of the breast.
Goldstein NS; Kestin LL; Vicini FA
Cancer; 2001 Aug; 92(4):738-47. PubMed ID: 11550142
[TBL] [Abstract][Full Text] [Related]
39. Mammary endocrine ductal carcinoma in situ: a case report.
Danikas D; Matthews WE; Averbach DJ
Am Surg; 2000 Dec; 66(12):1163-4. PubMed ID: 11149590
[TBL] [Abstract][Full Text] [Related]
40. Management of lobular carcinoma in-situ and atypical lobular hyperplasia of the breast--a review.
Hussain M; Cunnick GH
Eur J Surg Oncol; 2011 Apr; 37(4):279-89. PubMed ID: 21306860
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
